Coronado Research, a consultancy-led, professional services organization providing support to pharmaceutical, biotechnology, and medical device companies, has appointed Stephen Ralston as Executive Vice President Market Access and Health Economics Outcomes Research (HEOR). Ralston brings more than 25 years of experience providing strategic Market Access and HEOR solutions, at companies including Genesis Research Group, Takeda and Merck Serono.

Stephen brings extensive experience to Coronado Research, having played a key role in the establishment of new treatments across therapy areas including oncology, rare disease and immunology. He has previously held leadership roles in pharmaceutical companies, and his own Market Access and HEOR consultancy.

Within his new role at Coronado Research, Stephen will help customers navigate the complexities of the industry while ensuring the delivery of high-quality, impactful solutions, using his unique understanding of the challenges clients face in developing strategies and evidence for new assets.

Andrew MacGarvey, CEO of Coronado Research, said, “I am delighted to bring Stephen into Coronado Research to lead our Market Access and HEOR services. He is a fantastic addition to our leadership team and will play an essential role in helping our customers provide patients with better access to innovative therapies. He brings expertise highly complementary to our other functions, enabling us to join the dots between clinical development and commercial activities.”

Stephen Ralston, EVP Market Access and HEOR at Coronado Research, added, “It is an exciting time within Coronado Research as the business continues to experience unprecedented growth. I am looking forward to working with our established and talented team to offer our customers guidance into market access and HEOR strategies as they continue to develop therapies that benefits patients globally.”